Suppr超能文献

大塚制药复方制剂的通便作用可能与结肠中水通道蛋白 3 表达减少有关。

Laxative effect of repeated Daiokanzoto is attributable to decrease in aquaporin-3 expression in the colon.

机构信息

Global Research Center for Innovative Life Science, Hoshi University, Tokyo, Japan.

Division of Applied Pharmaceutical Education and Research, Hoshi University, Tokyo, Japan.

出版信息

J Nat Med. 2018 Mar;72(2):493-502. doi: 10.1007/s11418-018-1174-1. Epub 2018 Jan 27.

Abstract

Daiokanzoto (DKT) exerts its laxative effect via colonic inflammation caused by sennoside A in Daio (rhubarb). Previously, we showed that the laxative effect of sennoside A is related to decreased aquaporin-3 (AQP3) expression in mucosal epithelial cells due to colonic inflammation. We also found that a combination of glycyrrhizin, an ingredient in Kanzo (glycyrrhiza), and sennoside A attenuates the inflammatory response induced by sennoside A and reduces its laxative effect. These findings indicate that DKT may be a long-term treatment for chronic constipation, but there is no evidence supporting this hypothesis. In this study, we analyzed the laxative effect of repeated DKT administration, focusing on AQP3 expression in the colon. After rats were treated for 7 days, decreased AQP3 expression and the onset of diarrhea were observed in the DKT group, but were not seen in the Daio group either. Although the relative abundance of gut microbiota after repeated DKT administration was similar to that after control treatment, Daio reduced Lactobacillaceae, Bifidobacteriaceae, and Bacteroidaceae levels and markedly increased Lachnospiraceae levels. In this study, we show that DKT has a sustained laxative effect, even upon repeated use, probably because it maintains decreased AQP3 expression and gut microbiota homeostasis. This outcome therefore indicates that DKT can be used as a long-term treatment for chronic constipation.

摘要

大柴胡汤(DKT)通过番泻苷 A 在大肠引起的炎症发挥其通便作用。此前,我们表明番泻苷 A 的通便作用与由于大肠炎症导致的黏膜上皮细胞中水通道蛋白 3(AQP3)表达减少有关。我们还发现,甘草酸(甘草中的一种成分)和番泻苷 A 的组合可减轻番泻苷 A 诱导的炎症反应并降低其通便作用。这些发现表明 DKT 可能是慢性便秘的长期治疗方法,但没有证据支持这一假设。在这项研究中,我们分析了重复 DKT 给药的通便作用,重点关注结肠中的 AQP3 表达。在大鼠治疗 7 天后,DKT 组观察到 AQP3 表达减少和腹泻发作,但在 Daio 组均未观察到。尽管重复 DKT 给药后肠道微生物群的相对丰度与对照治疗相似,但 Daio 降低了乳杆菌科、双歧杆菌科和拟杆菌科的水平,并显著增加了lachnospiraceae 的水平。在这项研究中,我们表明 DKT 具有持续的通便作用,即使重复使用,这可能是因为它维持 AQP3 表达的减少和肠道微生物群的平衡。因此,这一结果表明 DKT 可作为慢性便秘的长期治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/6469848/5d61a612b007/11418_2018_1174_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验